Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | VDR | P11473 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490 | 0.91 | GAA (0.59) | HTTSMN1; SMN2VDRGAACA12 | |
| SCHEMBL64190 | 0.90 | VDR (0.49) | HTTSMN1; SMN2VDRGAACA12 | |
| SCHEMBL3144536 | 0.90 | VDR (0.49) | HTTSMN1; SMN2VDRGAACA12 | |
| SCHEMBL2955938 | 0.90 | VDR (0.49) | HTTSMN1; SMN2VDRGAACA12 | |
| SCHEMBL2962485 | 0.90 | VDR (0.49) | HTTSMN1; SMN2VDRGAACA12 | |
| SCHEMBL2964106 | 0.90 | VDR (0.49) | HTTSMN1; SMN2VDRGAACA12 | |
| Water SCHEMBL3352692 | 0.89 | GAA (0.56) | HTTSMN1; SMN2VDRGAACA12 | |
| SCHEMBL30862469 | 0.89 | GAA (0.56) | HTTSMN1; SMN2VDRGAACA12 | |
| SCHEMBL64622 | 0.88 | VDR (0.47) | HTTSMN1; SMN2VDRGAACA12 | |
| SCHEMBL3839712 | 0.88 | VDR (0.47) | HTTSMN1; SMN2VDRGAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951103-B2 | Pharmaceutical composition | KYOWA KIRIN CO., LTD. (JP) | 2024-04-09 | — | — | US | claimed |
| CN-115551505-A | Treatment of viral infections, diseases or conditions using selective S1R agonists | 普瑞尼亚神经治疗有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-117964442-A | Method for preparing polysubstituted alkylaromatic hydrocarbon, polysubstituted alkylaromatic hydrocarbon prepared by the method and application thereof | 中国石油化工股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-107615168-B | Radiation-sensitive composition | 日产化学工业株式会社 | 2023-12-19 | — | — | CN | disclosed |
| CN-117215155-A | Resist underlayer film material, pattern forming method, and resist underlayer film forming method | 信越化学工业株式会社 | 2023-12-12 | — | — | CN | disclosed |
| CN-110914241-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-117008420-A | Radiation-sensitive composition | 日产化学工业株式会社 | 2023-11-07 | — | — | CN | disclosed |
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2023-11-07 | — | — | US | disclosed |
| US-11676814-B2 | Material for forming organic film, substrate for manufacturing semiconductor apparatus, method for forming organic film, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| CN-115551505-A | Treatment of viral infections, diseases or conditions using selective S1R agonists | 普瑞尼亚神经治疗有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115368412-A | Method for preparing minodronic acid | 扬子江药业集团北京海燕药业有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| EP-1037586-A1 | UTILIZATION OF ONIUM ALDEHYDES AND ONIUM KETONES FOR DYING FIBERS CONTAINING KERATIN | Henkel Kommanditgesellschaft auf Aktien (DE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999018916-A2 | UTILIZATION OF ONIUM ALDEHYDES AND ONIUM KETONES FOR DYING FIBERS CONTAINING KERATIN | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1999-04-22 | — | — | WO | disclosed |
| EP-0882024-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997021685-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | disclosed |
| US-4281176-A | ESTERIFICATION OF ETHYLENE WITH A CARBOXYLIC ACID IN THE PRESENCE OF AN ACID CATALYST | RHONE-POULENC INDUSTRIES (FR) | 1981-07-28 | — | — | US | disclosed |
| US-4242510-A | Cephalosporin compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
| US-4118571-A | ANTIALLERGENS | STERLING DRUG INC. (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | MUSK, MERTK, PRKDC | HTT 4149/4885SMN1; SMN2 907/4885VDR 1754/4885 |
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | HTT 3453/4885SMN1; SMN2 4867/4885VDR 116/4885 |
| US-11951103-B2 | Pharmaceutical composition | EGFR, VEGFA, KDR | HTT 725/4885SMN1; SMN2 3118/4885VDR 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.